Moderna Covid-19 vaccine patent dispute headed to court, US NIH head says
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Tuesday
February 07, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
TUESDAY, FEBRUARY 07, 2023
Moderna Covid-19 vaccine patent dispute headed to court, US NIH head says

Coronavirus chronicle

Reuters
11 November, 2021, 12:10 pm
Last modified: 11 November, 2021, 12:14 pm

Related News

  • Variant-adapted Covid vaccine wins first approval in Britain
  • Apple files ‘bold’ patent
  • US to share Covid vaccine technology, Biden tells global summit
  • Covid vaccine maker Moderna flags Japan ambition with sumo sponsorship
  • Moderna seeks FDA authorisation for second Covid booster for all adults

Moderna Covid-19 vaccine patent dispute headed to court, US NIH head says

Moderna expects 2021 sales of $15 billion to $18 billion from the Covid-19 vaccine - its first and only commercial product - and up to $22 billion next year

Reuters
11 November, 2021, 12:10 pm
Last modified: 11 November, 2021, 12:14 pm
REUTERS/Dado Ruvic/Illustration
REUTERS/Dado Ruvic/Illustration

US National Institutes of Health scientists played "a major role" in developing Moderna Inc's Covid-19 vaccine and the agency intends to defend its claim as co-owner of patents on the shot, NIH Director Dr. Francis Collins told Reuters on Wednesday.

In a story first reported by the New York Times on Tuesday, Moderna excluded three NIH scientists as co-inventors of a central patent for the company's multibillion-dollar Covid-19 vaccine in its application filed in July.

"I think Moderna has made a serious mistake here in not providing the kind of co-inventorship credit to people who played a major role in the development of the vaccine that they're now making a fair amount of money off of," Collins said in an interview ahead of the Reuters Total Health conference, which will run virtually from Nov. 15-18. 

Moderna expects 2021 sales of $15 billion to $18 billion from the Covid-19 vaccine - its first and only commercial product - and up to $22 billion next year.

In a statement emailed to Reuters, Moderna acknowledged that scientists at NIH's National Institute of Allergy and Infectious Diseases (NIAID) played a "substantial role" in developing Moderna's messenger RNA (mRNA) vaccine, but the company said it disagrees with the agency's patent claims.

Collins said the NIH has been trying to resolve the patent conflict with Moderna amicably for some time and has failed.

"But we are not done. Clearly this is something that legal authorities are going to have to figure out," he said.

NIH has asserted that three of its scientists - Dr. John Mascola, Dr. Barney Graham and Dr. Kizzmekia Corbett - helped design the genetic sequence used in Moderna's vaccine and should be named on the patent application. Graham has since retired and Corbett is now working at Harvard.

"It's not a good idea to file a patent when you leave out important inventors, and so this is going to get sorted as people look harder at this," Collins told Reuters.

"I did not expect that to be the outcome from what had been a very friendly, collaborative effort between scientists at NIH and Moderna over many years."

In its statement, Moderna said, "We do not agree that NIAID scientists co-invented claims to the mRNA-1273 sequence itself. Only Moderna's scientists came up with the sequence for the mRNA used in our vaccine."

Moderna said the company has acknowledged NIH scientists in other patent applications, such as those related to dosing. But for the core patent, Moderna is only required to list Moderna scientists as inventors of the sequence under the strict rules of US patent law, it said.

"We are grateful for our collaboration with NIH scientists, value their contributions, and remain focused on working together to help patients," the company added.

World+Biz

Moderna Covid-19 Vaccine / patent

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Infographic: TBS
    FDI from US halves after sanctions
  • Muhammet Ruzgar, 5, is carried out by rescuers from the site of a damaged building, following an earthquake in Hatay, Turkey, February 7, 2023. REUTERS/Umit Bektas
    Rescue workers 'exhausted' as earthquake deaths cross 5,000 in Turkey, Syria
  • Photo: TBS
    BNP to hold march programmes in Dhaka on 9 and 12 February

MOST VIEWED

  • Tourists ride a tour bus in Hong Kong, China October 25, 2019. REUTERS/Ammar Awad
    Hong Kong will give away half a million plane tickets. Here’s who can get them first
  • People wearing face masks following the coronavirus disease (Covid-19) outbreak are seen at Beijing Daxing International Airport in Beijing, China July 23, 2020. Photo:Reuters
    Pandemic to paradise: Chinese tourists return to Bali after three years
  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs

Related News

  • Variant-adapted Covid vaccine wins first approval in Britain
  • Apple files ‘bold’ patent
  • US to share Covid vaccine technology, Biden tells global summit
  • Covid vaccine maker Moderna flags Japan ambition with sumo sponsorship
  • Moderna seeks FDA authorisation for second Covid booster for all adults

Features

Nimah designed by Compass Architects- Wooden tiles. Photo: Junaid Hasan Pranto

Trendy flooring designs to upgrade any space

6h | Habitat
Benefits of having high ceilings in your new home

Benefits of having high ceilings in your new home

6h | Habitat
Each Reverse Osmosi plant can produce approximately 8,000 litres of drinking water a day for around 250 families. Photo: Sadiqur Rahman

A drop in the ocean of persistent water crisis

7h | Panorama
Photo: Collected

Get your partner a lovely present this Valentine's Day

1d | Brands

More Videos from TBS

Challenging time waiting for RMG

Challenging time waiting for RMG

5h | TBS Round Table
"Full Moon Meditation" organized by Department of Theater and Performance Studies, University of Dhaka

"Full Moon Meditation" organized by Department of Theater and Performance Studies, University of Dhaka

5h | TBS Graduates
10 cricketers who have played over 400 T20 matches

10 cricketers who have played over 400 T20 matches

5h | TBS SPORTS
Harry Kane sets two record in one goal

Harry Kane sets two record in one goal

5h | TBS SPORTS

Most Read

1
Photo: Courtesy
Panorama

From 'Made in Bangladesh' to 'Designed in Bangladesh'

2
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

3
Master plan for futuristic Chattogram city in the making
Districts

Master plan for futuristic Chattogram city in the making

4
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

5
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

6
Photo: Collected
Crime

Prime Distribution MD Mamun arrested in fraud case

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]